Hangzhou Yanzhen Biotech Co., Ltd. is committed to the whole genome sequencing of newborns.

The Global Emerging Technology Summit (EmTech China) has hosted and invited top scientists, technology leaders and young tech pioneers from dozens of world-renowned institutions, including Google, Amazon, Microsoft, Alibaba, Tencent, Hkita, and the Massachusetts Institute of Technology, to share their exclusive insights into the world's cutting-edge technology trends. At the
Summit, Dr. Zhao Yanning, co-founder and chairman of Hangzhou Yanzhen Biotech Co., Ltd., delivered a presentation entitled "When the Genome Meets Artificial Intelligence" and participated in a round-table discussion in the biomedical sector.
Zhao Yanning admitted that, compared with 25 years ago, despite the endless scientific and technological means, but the medical treatment of a wide range of diseases can still do a cup of water.
genetic testing allows people to understand the risks in advance and respond to all aspects of life, starting with four "Ds" and covering the biomedical field, namely Diagnostics, Big Data, Drug Discovery and Drug Development.
in the field of genetic data and drug research and development, Zhao Put forward the concept of "three-step", that is, to establish a platform and access to high-quality genomic data of the general population and patients, to integrate and mine the data, and finally to use the data for new drug development and health management.
in scientific research, Zhao and his team are generating a distributed information ecosystem through Arvados, the cloud platform of Hangzhou Yanzhen Biotech Co., Ltd., where researchers around the world can benefit from genome-wide sequencing by gaining access to high-quality data.
"Big data is not simply putting all the data in, but is able to intelligently filter the targets you need, believing that artificial intelligence and machine learning can do the job."
," Mr Zhao said.
in the field of consumer genetic testing, Zhao said, the real creature is not simply after sequencing to give customers a few hundred pages of report, but in the future to introduce machine learning and artificial intelligence to build a genome interpretation platform. "We wanted to create a interpretation system where people interact with genomic data,"
.
machine learning allows data to be updated frequently, and artificial intelligence gives people real-time insight into the latest interpretations of their genes.
," Zhao said.
With the launch of last year's "Kaizhen myBabyGenome" baby genome sequencing product, He proposed that Hangzhou Yanzhen Biotech Co., Ltd. will be committed to the future of every newborn in a major city for genome-wide sequencing, even whole-group sequencing (microbiome, immune groups, etc.).
this "gene ID card" is not only for medical research, but also for children to get a full range of health management at an early stage.
it is understood that Hangzhou Yanzhen Biotech Co., Ltd. was named "the 50 Smartest Companies in the World" by the Massachusetts Institute of Technology Review for two consecutive years in 2016 and 2017, and the only company in China to make the list in the field of genetic biology.
.